Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $89.90 Consensus PT from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have been given a consensus rating of "Buy" by the thirteen research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $89.90.

Several analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $200.00 target price on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Scotiabank raised their price objective on Janux Therapeutics from $42.00 to $62.00 and gave the company a "sector perform" rating in a research report on Wednesday, December 4th. Stifel Nicolaus boosted their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a "buy" rating in a report on Tuesday, December 3rd. Leerink Partnrs upgraded shares of Janux Therapeutics to a "strong-buy" rating in a report on Friday, November 22nd. Finally, BTIG Research lifted their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, December 3rd.

Janux Therapeutics Stock Up 1.9 %

Shares of NASDAQ JANX traded up $0.67 during midday trading on Friday, reaching $36.78. 690,727 shares of the company's stock traded hands, compared to its average volume of 1,099,165. The company has a market cap of $1.93 billion, a price-to-earnings ratio of -31.44 and a beta of 3.16. The stock's 50 day simple moving average is $50.54 and its 200-day simple moving average is $48.23. Janux Therapeutics has a one year low of $7.81 and a one year high of $71.71.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 13,334 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the transaction, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $51.60, for a total transaction of $1,290,000.00. Following the sale, the chief executive officer now owns 257,054 shares of the company's stock, valued at approximately $13,263,986.40. The trade was a 8.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 86,668 shares of company stock worth $4,872,515. Company insiders own 29.40% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. FMR LLC boosted its position in Janux Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company's stock worth $355,475,000 after purchasing an additional 47,075 shares in the last quarter. Janus Henderson Group PLC boosted its holdings in Janux Therapeutics by 40.0% during the third quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company's stock worth $114,587,000 after buying an additional 721,563 shares in the last quarter. Vanguard Group Inc. grew its position in Janux Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company's stock valued at $114,379,000 after buying an additional 288,402 shares during the period. Geode Capital Management LLC increased its holdings in Janux Therapeutics by 7.9% in the fourth quarter. Geode Capital Management LLC now owns 714,956 shares of the company's stock valued at $38,288,000 after buying an additional 52,362 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in shares of Janux Therapeutics by 3,592.9% in the fourth quarter. Wellington Management Group LLP now owns 535,396 shares of the company's stock worth $28,665,000 after acquiring an additional 520,898 shares during the period. Hedge funds and other institutional investors own 75.39% of the company's stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.